18.34
price up icon1.10%   0.20
after-market Handel nachbörslich: 18.34
loading
Schlusskurs vom Vortag:
$18.14
Offen:
$18.07
24-Stunden-Volumen:
206.78K
Relative Volume:
0.60
Marktkapitalisierung:
$603.00M
Einnahmen:
$4.12M
Nettoeinkommen (Verlust:
$-56.68M
KGV:
-3.3087
EPS:
-5.5429
Netto-Cashflow:
$-51.44M
1W Leistung:
+5.16%
1M Leistung:
-0.46%
6M Leistung:
-19.91%
1J Leistung:
-24.34%
1-Tages-Spanne:
Value
$17.11
$18.41
1-Wochen-Bereich:
Value
$16.64
$18.48
52-Wochen-Spanne:
Value
$13.37
$32.27

Dianthus Therapeutics Inc Stock (DNTH) Company Profile

Name
Firmenname
Dianthus Therapeutics Inc
Name
Telefon
929-999-4055
Name
Adresse
7 TIMES SQUARE, NEW YORK
Name
Mitarbeiter
78
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
DNTH's Discussions on Twitter

Vergleichen Sie DNTH mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
DNTH
Dianthus Therapeutics Inc
18.34 603.00M 4.12M -56.68M -51.44M -5.5429
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.82 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
520.29 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
321.82 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.53 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
267.12 28.51B 3.81B -644.79M -669.77M -6.24

Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-20 Eingeleitet TD Cowen Buy
2024-10-03 Eingeleitet Oppenheimer Outperform
2024-07-26 Eingeleitet Robert W. Baird Outperform
2024-06-27 Eingeleitet Cantor Fitzgerald Overweight
2024-05-16 Eingeleitet H.C. Wainwright Buy
2024-02-15 Eingeleitet Stifel Buy
2023-12-26 Eingeleitet Jefferies Buy
2023-11-22 Eingeleitet Wedbush Outperform
2023-10-30 Eingeleitet Guggenheim Buy
2023-09-28 Eingeleitet Raymond James Outperform
2022-08-25 Herabstufung Goldman Buy → Neutral
2022-01-06 Hochstufung Goldman Neutral → Buy
2021-08-20 Fortgesetzt Goldman Neutral
2021-08-03 Herabstufung JP Morgan Overweight → Neutral
2021-07-22 Bestätigt B. Riley Securities Buy
2021-06-29 Eingeleitet Cantor Fitzgerald Overweight
2021-06-15 Eingeleitet BTIG Research Buy
2021-05-18 Eingeleitet B. Riley Securities Buy
2021-01-07 Eingeleitet Mizuho Buy
2020-06-08 Hochstufung Goldman Neutral → Buy
2019-03-25 Herabstufung Goldman Buy → Neutral
2019-03-15 Eingeleitet Raymond James Outperform
Alle ansehen

Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten

pulisher
Jun 18, 2025

Buy Rating for Dianthus Therapeutics: Promising Growth Potential of DNTH103 in Neuromuscular Disease Treatment - TipRanks

Jun 18, 2025
pulisher
Jun 14, 2025

Equities Analysts Issue Forecasts for DNTH FY2026 Earnings - MarketBeat

Jun 14, 2025
pulisher
Jun 13, 2025

Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 4.6%What's Next? - MarketBeat

Jun 13, 2025
pulisher
Jun 13, 2025

California State Teachers Retirement System Sells 1,352 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Two Sigma Investments LP Sells 588 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World

Jun 12, 2025
pulisher
Jun 08, 2025

Squarepoint Ops LLC Has $242,000 Stock Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Millennium Management LLC Has $1.97 Million Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat

Jun 07, 2025
pulisher
Jun 05, 2025

Bank of America Corp DE Sells 9,858 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World

Jun 05, 2025
pulisher
Jun 03, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Acquired by Millennium Management LLC - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

BNP Paribas Financial Markets Makes New Investment in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World

Jun 03, 2025
pulisher
Jun 01, 2025

Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 5.2%Time to Sell? - MarketBeat

Jun 01, 2025
pulisher
May 31, 2025

Analysts Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) PT at $53.00 - MarketBeat

May 31, 2025
pulisher
May 30, 2025

Deutsche Bank AG Increases Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World

May 30, 2025
pulisher
May 29, 2025

Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference - The Manila Times

May 29, 2025
pulisher
May 29, 2025

Autoimmune Disease Biotech Dianthus Therapeutics CEO Takes Stage at Major Jefferies Conference - Stock Titan

May 29, 2025
pulisher
May 26, 2025

Northern Trust Corp Acquires 42,923 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat

May 26, 2025
pulisher
May 26, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Purchased by Woodline Partners LP - MarketBeat

May 26, 2025
pulisher
May 26, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Recommendation of “Buy” from Brokerages - Defense World

May 26, 2025
pulisher
May 25, 2025

Point72 Asset Management L.P. Reduces Stock Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat

May 25, 2025
pulisher
May 24, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Acquired by Vestal Point Capital LP - MarketBeat

May 24, 2025
pulisher
May 23, 2025

Dianthus Therapeutics appoints new board member By Investing.com - Investing.com India

May 23, 2025
pulisher
May 23, 2025

Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors - citybiz

May 23, 2025
pulisher
May 22, 2025

Dianthus Therapeutics appoints new board member - Investing.com Australia

May 22, 2025
pulisher
May 22, 2025

Dianthus Therapeutics Announces Board Changes and Elections - TipRanks

May 22, 2025
pulisher
May 22, 2025

Former Novartis-Acquired CEO Joins Dianthus Board Ahead of Critical Phase 2 Data - Stock Titan

May 22, 2025
pulisher
May 21, 2025

Janus Henderson Group PLC Buys 136,314 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat

May 21, 2025
pulisher
May 20, 2025

Buy Rating Affirmed for Dianthus Therapeutics: Promising Clinical Potential of DNTH103 in CIDP Treatment - TipRanks

May 20, 2025
pulisher
May 19, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Position Raised by Octagon Capital Advisors LP - MarketBeat

May 19, 2025
pulisher
May 18, 2025

Robert W. Baird Has Lowered Expectations for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - MarketBeat

May 18, 2025
pulisher
May 18, 2025

FY2025 EPS Estimates for DNTH Lowered by Cantor Fitzgerald - Defense World

May 18, 2025
pulisher
May 18, 2025

Dianthus Therapeutics (NASDAQ:DNTH) Earns "Buy" Rating from HC Wainwright - MarketBeat

May 18, 2025
pulisher
May 17, 2025

Dianthus Therapeutics (NASDAQ:DNTH) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat

May 17, 2025
pulisher
May 17, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Bought by Price T Rowe Associates Inc. MD - Defense World

May 17, 2025
pulisher
May 16, 2025

Wedbush Research Analysts Raise Earnings Estimates for DNTH - Defense World

May 16, 2025
pulisher
May 16, 2025

HC Wainwright Issues Positive Forecast for DNTH Earnings - Defense World

May 16, 2025
pulisher
May 16, 2025

Tower Research Capital LLC TRC Sells 944 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World

May 16, 2025
pulisher
May 15, 2025

Robert W. Baird Issues Pessimistic Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - Defense World

May 15, 2025
pulisher
May 15, 2025

HC Wainwright Reaffirms Buy Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World

May 15, 2025

Finanzdaten der Dianthus Therapeutics Inc-Aktie (DNTH)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.52
price down icon 1.06%
$35.91
price down icon 0.64%
$21.27
price up icon 1.67%
$104.85
price down icon 0.99%
$104.80
price down icon 0.28%
biotechnology ONC
$267.12
price up icon 0.12%
Kapitalisierung:     |  Volumen (24h):